Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20957019 | 0.89 | MAPT (0.48) | GFERL3MBTL1MAPTGAATP53 | |
| SCHEMBL31467485 | 0.89 | MAPT (0.48) | GFERL3MBTL1MAPTGAATP53 | |
| SCHEMBL20988353 | 0.88 | MAPT (0.47) | GFERL3MBTL1MAPTGAATP53 | |
| SCHEMBL20957054 | 0.88 | MAPT (0.47) | GFERL3MBTL1MAPTGAATP53 | |
| SCHEMBL20956995 | 0.86 | GAA (0.46) | GFERL3MBTL1MAPTGAATP53 | |
| SCHEMBL31467495 | 0.82 | MAPT (0.44) | GFERL3MBTL1MAPTGAATP53 | |
| SCHEMBL31467509 | 0.80 | MAPT (0.51) | GFERL3MBTL1MAPTGAATP53 | |
| SCHEMBL31467503 | 0.78 | MAPT (0.72) | GFERL3MBTL1MAPTGAATP53 | |
| SCHEMBL20957055 | 0.78 | MAPT (0.50) | GFERL3MBTL1MAPTGAATP53 | |
| SCHEMBL26299189 | 0.77 | SLC6A2 (0.42) | GFERL3MBTL1MAPTGAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481801-B1 | INDOLINE DERIVATIVES AND METHOD FOR USING AND PRODUCING THE SAME | UNIV ARIZONA (US) | 2023-09-06 | — | — | EP | disclosed |
| US-10654802-B2 | Indoline derivatives and method for using and producing the same | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNVERSIT (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190135746-A1 | INDOLINE DERIVATIVES AND METHOD FOR USING AND PRODUCING THE SAME | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNVERSITY OF ARIZONA | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654802-B2 | Indoline derivatives and method for using and producing the same | IDO1, IDO2, MMP1 | GFER 2822/4885L3MBTL1 3712/4885MAPT 1971/4885 |
| US-20190135746-A1 | INDOLINE DERIVATIVES AND METHOD FOR USING AND PRODUCING THE SAME | IDO1, INMT, MMP1 | GFER 1690/4885L3MBTL1 4531/4885MAPT 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.